Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 9/20 | 0.76 |
| ▸ | ALPI | P09923 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | XIAP | P98170 | 1/20 | 0.54 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CTSH | P09668 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9144573 | 1.00 | CTSC (0.76) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL1691349 | 1.00 | CTSC (0.76) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL9389290 | 1.00 | CTSC (0.76) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL583121 | 1.00 | CTSC (0.76) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL2813084 | 0.98 | CTSC (0.74) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL4588611 | 0.98 | CTSC (0.74) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL9293695 | 0.93 | CTSC (0.67) | CTSCSLC7A5CYP1A2CYP3A4CTSH | |
| SCHEMBL5996736 | 0.93 | CTSC (0.67) | CTSCSLC7A5CYP1A2CYP3A4CTSH | |
| SCHEMBL8893265 | 0.93 | CTSC (0.67) | CTSCSLC7A5CYP1A2CYP3A4CTSH | |
| SCHEMBL9143188 | 0.93 | CTSC (0.67) | CTSCSLC7A5CYP1A2CYP3A4CTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155800-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2021-10-26 | — | — | US | claimed |
| US-20210077468-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2021-03-18 | — | — | US | claimed |
| US-20200283748-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2020-09-10 | — | — | US | claimed |
| US-10557128-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2020-02-11 | — | — | US | claimed |
| US-20180303950-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2018-10-25 | — | — | US | claimed |
| US-9951324-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2018-04-24 | — | — | US | claimed |
| US-20160151508-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2016-06-02 | — | — | US | claimed |
| CN-104873982-A | PSMA binding ligand-linker conjugates and methods of use thereof | PURDUE RESEARCH FOUNDATION | 2015-09-02 | — | — | CN | claimed |
| US-8669229-B2 | Benzazepine derivatives useful as vasopressin antagonists | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-03-11 | — | — | US | claimed |
| CN-103342680-A | Benzazepine derivatives useful as vasopressin antagonists | OTSUKA PHARMA CO LTD | 2013-10-09 | — | — | CN | claimed |
| EP-2170831-A1 | BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-04-07 | — | — | EP | claimed |
| CN-101687805-A | Benzazepine derivatives useful as vasopressin antagonists | OTSUKA PHARMA CO LTD | 2010-03-31 | — | — | CN | claimed |
| WO-2009026177-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2009-02-26 | — | — | WO | claimed |
| WO-2009001968-A1 | BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-12-31 | — | — | WO | claimed |
| CN-1658819-A | Care and/or make-up cosmetic composition structured with silicone polymers and organogelling agents, in rigid form | OREAL (FR) | 2005-08-24 | — | — | CN | claimed |
| EP-1515684-A2 | CARE AND/OR MAKE-UP COSMETIC COMPOSITION STRUCTURED WITH SILICONE POLYMERS AND ORGANOGELLING AGENTS, IN RIGID FORM | L'OREAL (FR) | 2005-03-23 | — | — | EP | claimed |
| WO-2003105788-A2 | CARE AND/OR MAKE-UP COSMETIC COMPOSITION STRUCTURED WITH SILICONE POLYMERS AND ORGANOGELLING AGENTS, IN RIGID FORM | L'OREAL (FR) | 2003-12-24 | — | — | WO | claimed |
| EP-0272671-B1 | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors | SANDOZ LTD (CH) | 1994-03-16 | — | — | EP | claimed |
| US-5055451-A | Prevent tissue damage | SYNTEX INC. (US) | 1991-10-08 | — | — | US | claimed |
| EP-0272671-A2 | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors | SANDOZ LTD. (CH) | 1988-06-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210077468-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CTSC 581/4885ALPI 865/4885PKM 1687/4885 |
| US-20200283748-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CTSC 572/4885ALPI 892/4885PKM 1736/4885 |
| US-11155800-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | CTSC 572/4885ALPI 892/4885PKM 1736/4885 |
| US-20180303950-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CTSC 581/4885ALPI 865/4885PKM 1687/4885 |
| US-20160151508-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CTSC 572/4885ALPI 892/4885PKM 1736/4885 |
| US-10557128-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | CTSC 572/4885ALPI 892/4885PKM 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.